Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetes, Immunosuppression
Interventions
Gastric emptying test
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis

NCT04762719
Conditions
Diabetes, Gastroparesis With Diabetes Mellitus
Interventions
PET/CT Scan with 11C-ER176, Core biopsy of gastric muscle
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Placebo, 10mg TZP-102, 20mg TZP-102
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 27 more
Conditions
Diabetic Gastroparesis
Interventions
CIN-102 Dose 15mg or 10mg, Placebo
Drug
Lead sponsor
CinDome Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
100
States / cities
Dothan, Alabama • Foley, Alabama • Huntsville, Alabama + 82 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effect of TU-100 on Gastrointestinal and Colonic Transit in Humans

NCT00871325
Conditions
Postoperative Ileus
Interventions
Daikenchuto (TU-100), Placebo
Drug
Lead sponsor
Tsumura USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Overweight, Obesity, Diabetes Mellitus, Type 2
Interventions
Tirzepatide, Acetaminophen
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hialeah, Florida
Completed No phase listed Observational Accepts healthy volunteers

Effect of Food Form on Satiety and Gastric Emptying

NCT01102907
Conditions
Appetite
Interventions
Liquid Breakfast, Solid Breakfast Meal
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Terminated Not applicable Interventional Accepts healthy volunteers

Tricyclic Antidepressants (TCAs) on Gastric Emptying

NCT00220844
Conditions
Dyspepsia
Interventions
Desipramine, Amitriptyline
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Results available

Vagal Nerve Stimulation and Glucose Metabolism

NCT01117311
Conditions
Type 2 Diabetes, Obesity, Gastric Emptying
Interventions
VNB on, VNB off
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Obesity, Obesity, Morbid, Obesity, Primary, Metabolic Disease, Delayed Gastric Emptying Following Procedure
Interventions
PSAM Treatment Patients
Procedure
Lead sponsor
Christopher C. Thompson, MD, MSc
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Gastroparesis
Interventions
GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet), Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Concord, California • Indianapolis, Indiana • Chevy Chase, Maryland + 6 more
Conditions
Functional Constipation
Interventions
DAIKENCHUTO (TU-100), Placebo
Drug
Lead sponsor
Tsumura USA
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Gastroparesis
Interventions
GSK962040 50 mg, Metoclopramide 10 mg, Placebo NG, Placebo IV
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Aurora, Colorado • Augusta, Georgia • Louisville, Kentucky + 1 more
Conditions
Obesity, Weight Loss, Delayed Gastric Emptying Following Procedure, Obesity, Mild, Obesity, Morbid, Obesity; Excess Calories
Interventions
Bariatric Endoscopic Antral Myotomy
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Gastroparesis, Gastroparesis-like Syndrome
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
8 Years to 25 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Columbus, Ohio • El Paso, Texas + 2 more
Completed Not applicable Interventional Accepts healthy volunteers

GEBT Lot-to-Lot and Biological Variability

NCT04772261
Conditions
Gastroparesis
Interventions
13C-Spirulina GEBT
Diagnostic Test
Lead sponsor
Cairn Diagnostics
Industry
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Brentwood, Tennessee
Conditions
Diabetic Gastroparesis
Interventions
Metoclopramide Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 46 more
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Teduglutide on Gastric Emptying in Healthy Subjects

NCT01209351
Conditions
Healthy Volunteers
Interventions
Placebo, teduglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Constipation
Interventions
Functional Magnetic Stimulation
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Chronic Constipation
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
65 Years and older
Enrollment
60 participants
Timeline
2006 – 2007
U.S. locations
3
States / cities
North Little Rock, Arizona • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Conditions
Gastroparesis
Interventions
Endoscopic per-oral pyloromyotomy (POP), Diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption
Procedure
Lead sponsor
Matthew Allemang
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

NCT02160990
Conditions
Obesity
Interventions
Exenatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota